Acute Complicated

Question 1

Is present in almost all patient with UTi

Answer 1

S

Question 2

Diagnostic approach

Answer 2

D

Question 3

Imaging

Answer 3

S

Question 4

Indications for hospitalization

Answer 4

K

Question 5

when patients are septic or otherwise critically ill.

Answer 5

J

Question 6

persistently high fever (eg, >38.4°C/>101°F) or pain,

Answer 6

J

Question 7

marked debility,

Answer 7

I

Question 8

inability to maintain oral hydration or take oral medications

Answer 8

I

Question 9

when urinary tract obstruction is suspected

Answer 9

I

Question 10

are alternatives to vancomycin.

Answer 10

I

Question 11

the
patient has not had a urinary isolate resistant to fluoroquinolones in the prior three
months and the community prevalence of E. coli fluoroquinolone resistance is not known
to be higher than 10 percent.

Answer 11

I

Question 12

If Enterococcus or Staphylococcus species are suspected (eg, because of prior
urinary isolates), piperacillin-tazobactam………because it has activity against
these organisms

Answer 12

L

Question 13

If patients have risk factors for an ESBL-producing organism, we avoid…….,

Answer 13

>

Question 14

If resistant Enterococcus species or MRSA are suspected (eg, because of prior urinary isolates), we add………

Answer 14

:

Question 15

attains lower urinary levels than other fluoroquinolones and should not be used.

Answer 15

I

Question 16

Moxifloxacin

Answer 16

<

Question 17

Directed antimicrobial therapy

Answer 17

K

Question 18

Enterobacterales (eg, E. coli, K. pneumoniae, P. mirabilis):

Answer 18

I

Question 19

Enterococcus

Answer 19

I

Question 20

Pseudomonas

Answer 20

K

Question 21

Staphylococcus

Answer 21

I

Question 22

Total duration of antimicrobial therapy generally ranges…….

Answer 22

L

Question 23

5 to 10 days,

Answer 23

I

Question 24

Acute UTI accompanied by signs or symptoms that suggest extension of infection beyond the bladder:

Answer 24

O

Question 25

Suspect multidrug-resistant gram-negative urinary tract infection in patients
with a history of any of the following in the prior three months:

Answer 25

I

Question 26

A multidrug-resistant gram-negative urinary isolate or a fluoroquinolone-resistant Pseudomonas aeruginosa isolate

Answer 26

I

Question 27

Travel to parts of the world with high rates of multidrug-resistant organisms
¶

Answer 27

K

Question 28

India, Israel, Spain, and Mexico.

Answer 28

I

Question 29

Antipseudomonal carbapenem ans vancomyin

Answer 29

D

Question 30

Ceftrixaone or pioeracillin tazobcatam or levofloxacin or ciprofloxacin

Answer 30

D

Question 31

Piperacillin tazobactam or cefepime or carbapenem

Answer 31

D

Question 32

Ceftriaxone or ertapenem or tobramycin followed by TMP-SMx or amoxicillin cłavulanate or cefpodxime or cefdinir or cefadroixl

Answer 32

>

Question 33

Ertapenem followed by ciprofloxacin or levofloxcin

Answer 33

L

Question 34

Not for ESbL risk

Answer 34

E

Question 35

7 to 10 days

Answer 35

D

Question 36

5 to 7 days

Answer 36

D